MALT lymphoma
MONDO:0007650An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells). The gastrointestinal tract is the most common site of involvement. Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast. Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)
Also known as: Extranodal marginal zone B-cell lymphoma, Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma), Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, Immunocytoma, MALT lymphoma, MALT-lymphoma, MALToma
2033 clinical trials for this condition and its sub-types, 30 tagged with MALT lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of MALT lymphoma
-
Tonsillar lymphoma 0 trials
-
Immunotherapy combo shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis phase 2 trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or combined with idelalisib or ibrutinib in 65 patients with chronic lymphocytic leukemia (CLL) or low-grade B-cell non-Hodgkin lymphoma (NHL) that had returned or stopped responding to treatment. The…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo shows promise for untreated lymphoma patients
Disease control CompletedThis study tested a combination of three targeted drugs (mosunetuzumab, polatuzumab vedotin, and obinutuzumab) in 42 people with untreated slow-growing B-cell non-Hodgkin lymphoma. The goal was to see how many patients achieved a complete response (no cancer detected). The drugs …
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo shows promise for tough lymphomas
Disease control CompletedThis study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting wors…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Battle of the bacteria: which drug combo wins against resistant h. pylori?
Disease control CompletedThis study tested two different drug combinations in 782 people with H. pylori infection that was resistant to the antibiotic clarithromycin. One group received a triple therapy with a proton pump inhibitor, amoxicillin, and metronidazole, while the other received a quadruple the…
Sponsor: Kangdong Sacred Heart Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC